<DOC>
	<DOCNO>NCT02005484</DOCNO>
	<brief_summary>This study evaluate efficacy safety Herceptin patient metastatic advanced gastric cancer disease progression platinum-based 5-fluoropyrimidine-based chemotherapy . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Patients With Metastatic Advanced Gastric Cancer With Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient 1875 year age ; metastatic advance gastric cancer ; disease progression 1 prior platinumbased 5fluoropyrimidinebased chemotherapy metastatic disease ; &gt; =4 week last platinumbased fluoropyrimidinebased chemotherapy ; &gt; =1 measurable lesion ; HER2 overexpression ( IHC [ 2+ ] [ 3+ ] ) . concurrent chemotherapy immunotherapy ; brain meningeal metastasis ; clinically significant cardiac disease , advance pulmonary disease severe dyspnoea ; coexist malignancy malignancy diagnose within last 5 year , except basal cell cancer cervical cancer situ ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>